Menu
Search
|

Menu

Close
X

Xencor Inc XNCR.OQ (NASDAQ Stock Exchange Global Market)

35.38 USD
-0.10 (-0.28%)
As of Sep 13
Previous Close 35.48
Open 35.69
Volume 101,971
3m Avg Volume 212,940
Today’s High 36.42
Today’s Low 35.11
52 Week High 48.31
52 Week Low 27.75
Shares Outstanding (mil) 46.93
Market Capitalization (mil) 1,163.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.91 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY19
131
FY18
41
FY17
46
FY16
109
EPS (USD)
FY19
1.096
FY18
-1.352
FY17
-0.823
FY16
1.058
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
36.42
7.91
Price to Book (MRQ)
vs sector
3.85
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
0.00
14.55
LT Debt to Equity (MRQ)
vs sector
0.00
10.20
Return on Investment (TTM)
vs sector
-14.67
14.48
Return on Equity (TTM)
vs sector
-15.16
15.78

EXECUTIVE LEADERSHIP

Bassil Dahiyat
President, Chief Executive Officer, Founder and Director, Since 2015
Salary: $550,000.00
Bonus: $453,750.00
John Desjarlais
Senior Vice President, Research and Chief Scientific Officer, Since 2016
Salary: $412,000.00
Bonus: $247,200.00
Paul Foster
Senior Vice President and Chief Medical Officer, Since 2015
Salary: $437,091.00
Bonus: $262,254.00
John Kuch
Vice President - Finance, Since 2010
Salary: $368,000.00
Bonus: $223,400.00
Jeremy Grunstein
Vice President of Business Development, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

111 W Lemon Ave
MONROVIA   CA   91016-2809

Phone: +1626.3055900

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

SPONSORED STORIES